Diagnosis of Functional Dyspepsia: Rome IV Criteria and Beyond

Abstract

Functional dyspepsia (FD) is a prevalent and challenging disorder characterized by chronic or recurrent upper gastrointestinal symptoms in the absence of structural disease. The Rome IV criteria represent the current consensus for diagnosis, but ongoing research reveals new dimensions in pathophysiology, diagnostic approaches, and management strategies. This comprehensive review synthesizes recent evidence, explores the clinical implications of the Rome IV criteria, discusses risk factors, diagnostic challenges, and reviews emerging therapies and guideline recommendations, providing a practical and up-to-date resource for medical professionals.

Introduction

Functional dyspepsia is a common functional gastrointestinal disorder (FGID) presenting with upper abdominal discomfort or pain, early satiety, bloating, and nausea. Despite its benign nature, FD significantly impairs patients quality of life and poses diagnostic and therapeutic challenges. The Rome IV criteria have refined the classification and diagnosis of FD, focusing on symptom-based definitions and exclusion of organic disease. This article reviews epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management, and recent advances, with a focus on clinical applicability.

Epidemiology / Disease Burden

FD affects approximately 10–20% of the global population, with higher prevalence in women and individuals aged 20–50 years. The disorder constitutes a significant proportion of gastroenterology outpatient visits and incurs substantial healthcare costs. In Asia, prevalence estimates range from 8% to 23%, while Western populations report rates between 10% and 15%. The chronic nature of FD and its relapsing course contribute to work absenteeism, decreased productivity, and impaired psychosocial well-being, underscoring the need for effective diagnostic and management approaches.

Pathophysiology

The pathophysiology of FD is multifactorial and incompletely understood. Major mechanisms include abnormal gastroduodenal motility, visceral hypersensitivity, altered gastric accommodation, low-grade mucosal inflammation, and disturbances in the gut–brain axis. Recent studies highlight the roles of duodenal eosinophilia, mast cell infiltration, and subtle changes in gut microbiota. Psychological factors such as anxiety and depression are frequently comorbid, suggesting a bidirectional relationship between brain and gut. These diverse mechanisms contribute to symptom heterogeneity and therapeutic complexity.

Risk Factors

Identified risk factors for FD include female sex, younger age, psychosocial stress, Helicobacter pylori infection, smoking, and early life adversity. Genetic predispositions, dietary habits, and previous gastrointestinal infections also play contributory roles. Notably, psychological distress, particularly anxiety and depression, often precede the onset of FD symptoms, implicating central nervous system modulation in disease pathogenesis. Recognizing these risk factors is essential for individualized patient assessment and management.

Clinical Features

FD is characterized by one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning. The Rome IV criteria further subclassify FD into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), based on predominant symptoms. Associated features may include nausea, belching, and upper abdominal bloating. Importantly, symptoms must be present for at least three months, with an onset at least six months before diagnosis, and should not be explained by structural disease on routine investigations.

Diagnosis

Diagnosis of FD is primarily clinical, guided by the Rome IV criteria and exclusion of organic pathology. Key diagnostic steps include a thorough history, physical examination, and selective use of investigations such as upper gastrointestinal endoscopy to rule out peptic ulcer, malignancy, and other structural causes in patients with alarm features or those over 50 years of age. Non-invasive tests for H. pylori, laboratory screening for metabolic disorders, and assessment of psychosocial factors are integral components. Additional diagnostic modalities such as gastric emptying studies and 13C-octanoic acid breath tests may be considered in refractory or complex cases, though their routine use is not recommended.

Treatment & Management

Management of FD is multifaceted and should be individualized. First-line therapy includes patient education, reassurance, and dietary modifications. Pharmacological interventions are guided by symptom subtypes: prokinetic agents (e.g., domperidone, itopride) are beneficial for PDS, while acid-suppressive therapy (proton pump inhibitors) is indicated for EPS. In patients with H. pylori infection, eradication therapy may result in symptom improvement. Adjunctive therapies include tricyclic antidepressants, selective serotonin reuptake inhibitors, and psychological interventions such as cognitive-behavioral therapy, particularly in patients with comorbid anxiety or depression. Multidisciplinary care is often required for refractory cases.

Recent Advances / Emerging Therapies

Recent advances in FD management include the exploration of neuromodulators, novel prokinetics, and gut microbiota-targeted therapies. Buspirone and acotiamide have shown promise in improving gastric accommodation, while rifaximin and probiotics are under investigation for their roles in modulating gut microbiota and inflammation. Endoscopic therapies and low-dose antidepressants are being evaluated in clinical trials. Advances in biomarker discovery and personalized medicine approaches hold potential for refining diagnosis and optimizing treatment response.

Guideline Recommendations

Contemporary guidelines, including those from the American College of Gastroenterology and the Rome Foundation, emphasize a symptom-based diagnosis with judicious use of diagnostic testing. Empirical therapy with acid suppression or prokinetics is recommended in the absence of alarm features. H. pylori testing and eradication are advocated where prevalence is high. Psychological interventions are recommended for patients with significant psychosocial distress or refractory symptoms. Shared decision-making and individualized care remain central to guideline-based management.

Conclusion

Functional dyspepsia remains a complex and heterogeneous disorder with substantial clinical and economic impact. The Rome IV criteria provide a robust framework for diagnosis, but emerging insights into pathophysiology, risk stratification, and novel therapies are expanding the therapeutic landscape. Clinicians should adopt a patient-centered, evidence-based approach, integrating guideline recommendations and emerging data to optimize outcomes for individuals with FD. Ongoing research into biomarkers and personalized medicine promises further advances in the diagnosis and management of this challenging condition.